Drug Interactions: Mechanisms, CYP450, P-Glycoprotein, and Clinical Management of Drug-Drug Interactions

Introduction

Drug-drug interactions (DDIs) occur when one drug alters the effect of another, potentially leading to therapeutic failure or toxicity. DDIs are responsible for up to 30% of adverse drug events and are a leading cause of hospitalization in older adults. Understanding mechanisms of DDIs is essential for safe prescribing, especially in patients on multiple medications (polypharmacy).

Types of Drug Interactions

Pharmacokinetic Interactions

Type	Description	Mechanism	Clinical Impact
Absorption	One drug alters absorption of another	Chelation (tetracycline + calcium), altered GI pH (PPI + ketoconazole), altered motility (opioids delay absorption)	Reduced or delayed effect of affected drug
Distribution	Competition for protein binding	Displacement of drug A from albumin by drug B (warfarin + NSAIDs)	Transient increase in free (active) fraction of displaced drug
Metabolism	Altered hepatic metabolism	CYP450 induction or inhibition	Most clinically significant DDI type
Excretion	Altered renal elimination	Competition for tubular secretion (penicillin + probenecid), altered urine pH (quinidine + HCTZ)	Increased or decreased elimination

Pharmacodynamic Interactions

Type	Effect	Example
Additive	Combined effect equals sum of individual effects	Alcohol + benzodiazepine (CNS depression)
Synergistic	Combined effect exceeds sum of individual effects	TMP-SMX (sequential folate blockade)
Antagonistic	One drug opposes the effect of another	Beta-agonist + beta-blocker (bronchoconstriction)
Potentiation	One drug enhances effect of another via different mechanism	Probenecid + penicillin (decreased renal clearance)

CYP450-Mediated Interactions

CYP3A4 (Most Abundant, ~50% of Drug Metabolism)

Characteristic	Details
Location	Liver (80%), intestine (20%)
Substrates	Statins (atorvastatin, simvastatin), CCBs (amlodipine, nifedipine, diltiazem), benzodiazepines (midazolam, alprazolam, triazolam), immunosuppressants (cyclosporine, tacrolimus), opioids (fentanyl, oxycodone), macrolides, HIV PIs, oral contraceptives, warfarin (S-enantiomer), tyrosine kinase inhibitors
Strong inhibitors	Ritonavir, cobicistat, clarithromycin, itraconazole, ketoconazole, voriconazole, grapefruit juice (intestinal), telithromycin, nefazodone
Moderate inhibitors	Erythromycin, fluconazole, verapamil, diltiazem, amiodarone, cimetidine, aprepitant, imatinib
Weak inhibitors	Ciprofloxacin, fluvoxamine, ranitidine, omeprazole, sertraline
Strong inducers	Rifampin, carbamazepine, phenytoin, St. John’s Wort, enzalutamide, mitotane
Moderate inducers	Phenobarbital, primidone, pioglitazone, bosentan, efavirenz, etravirine
Weak inducers	Modafinil, armodafinil, topiramate, felbamate, clobazam

CYP2D6 (Polymorphic, ~20% of Drug Metabolism)

Characteristic	Details
Location	Liver (predominantly)
Genetic phenotypes	Poor metabolizers (PM, 5-10% Caucasians, 1-2% Asians), intermediate metabolizers (IM), extensive metabolizers (EM, normal), ultrarapid metabolizers (UM, 1-10% depending on population)
Substrates	Beta-blockers (metoprolol, propranolol, timolol), antidepressants (TCAs, fluoxetine, paroxetine, venlafaxine), antipsychotics (haloperidol, risperidone, aripiprazole), opioids (codeine, tramadol, oxycodone), tamoxifen, donepezil, metoclopramide
Inhibitors	Paroxetine (strong), fluoxetine (strong), bupropion (strong), quinidine (strong), duloxetine (moderate), sertraline (weak), cimetidine (weak), amiodarone (weak)
Inducers	Not significantly induced (no known clinically relevant inducers)

CYP2C9 (~15% of Drug Metabolism)

Characteristic	Details
Substrates	Warfarin (S-enantiomer, more potent), phenytoin, glipizide, glimepiride, losartan, irbesartan, celecoxib, NSAIDs (diclofenac, ibuprofen, naproxen), fluvastatin, rosuvastatin (minor)
Inhibitors	Amiodarone (strong), fluconazole (strong), miconazole (strong), metronidazole (moderate), sulfamethoxazole (moderate), capecitabine (moderate), voriconazole (strong)
Inducers	Rifampin (strong), carbamazepine, phenobarbital, phenytoin, St. John’s Wort, aprepitant

CYP2C19 (~8% of Drug Metabolism)

Characteristic	Details
Substrates	Clopidogrel (prodrug, requires CYP2C19 activation), PPIs (omeprazole, lansoprazole, pantoprazole), citalopram, escitalopram, sertraline, diazepam, phenytoin (minor), voriconazole, cyclophosphamide
Inhibitors	Fluvoxamine (strong), fluoxetine (moderate), omeprazole (moderate), esomeprazole (moderate), ticlopidine (strong), felbamate (strong)
Inducers	Rifampin (strong), carbamazepine, phenytoin, St. John’s Wort, prednisone

CYP1A2 (~4% of Drug Metabolism)

Characteristic	Details
Substrates	Theophylline, caffeine, clozapine, olanzapine, tizanidine, melatonin, ramelteon, duloxetine, mirtazapine, propafenone, tacrine
Inhibitors	Fluvoxamine (strong), ciprofloxacin (strong), oral contraceptives (moderate), cimetidine (moderate), mexiletine (moderate), fluconazole (moderate)
Inducers	Cigarette smoking (strong, polycyclic aromatic hydrocarbons), carbamazepine (moderate), phenytoin (moderate), rifampin (moderate), broccoli/brussels sprouts

P-Glycoprotein (P-gp) Interactions

Characteristic	Details
Location	Intestine (efflux into lumen), liver (bile), kidney (urine), blood-brain barrier (CNS efflux), placenta
Substrates	Digoxin, dabigatran, rivaroxaban, apixaban, edoxaban, fexofenadine, loperamide, colchicine, methotrexate, vinca alkaloids, anthracyclines, HIV PIs, cyclosporine, tacrolimus, sirolimus
Inhibitors	Amiodarone, verapamil, diltiazem, quinidine, clarithromycin, itraconazole, ketoconazole, ritonavir, cyclosporine, carvedilol, ranolazine
Inducers	Rifampin, carbamazepine, phenytoin, St. John’s Wort, spironolactone

Clinically Significant Drug Interactions

Cardiovascular Drug Interactions

Drug Pair	Interaction	Mechanism	Severity	Management
Warfarin + amiodarone	Increased INR, bleeding risk	CYP2C9 (warfarin) inhibition by amiodarone	Major	Reduce warfarin 30-50% when starting amiodarone; monitor INR closely
Warfarin + rifampin	Decreased INR, thrombosis risk	CYP2C9 induction	Major	Increase warfarin dose 2-5x; monitor INR daily
Warfarin + NSAIDs	Increased bleeding	Pharmacodynamic (GI mucosal injury + antiplatelet effect + protein displacement)	Major	Avoid if possible; use PPI if unavoidable
Warfarin + acetaminophen >2 g/day	Increased INR (modest)	Unknown mechanism, possibly depletion of clotting factors	Moderate	Monitor INR; consider limiting acetaminophen dose
Clopidogrel + omeprazole	Reduced clopidogrel activation, increased CV events	CYP2C19 inhibition (clopidogrel prodrug activation)	Major	Use pantoprazole or avoid PPI with clopidogrel
Simvastatin + clarithromycin	Increased statin level, rhabdomyolysis risk	CYP3A4 inhibition	Major	Avoid; use atorvastatin or fluvastatin instead
Simvastatin + grapefruit juice (large amount)	Increased statin level	Intestinal CYP3A4 inhibition	Major	Limit grapefruit juice; use pravastatin or rosuvastatin
Digoxin + amiodarone	Digoxin toxicity	P-gp inhibition	Major	Reduce digoxin dose 50% when starting amiodarone
Beta-blocker + CCB (verapamil/diltiazem)	Bradycardia, heart block	Additive AV node depression	Major	Avoid combination or use with caution, monitor HR

Antimicrobial Interactions

Drug Pair	Interaction	Mechanism	Severity	Management
Methotrexate + TMP-SMX	Methotrexate toxicity	Additive antifolate effect + decreased renal MTX excretion	Major	Avoid; use alternative antibiotic
Methotrexate + penicillins	MTX toxicity	Decreased renal MTX excretion	Moderate	Monitor MTX levels
Isoniazid + phenytoin	Phenytoin toxicity	CYP2C9 inhibition	Moderate	Monitor phenytoin levels
Ciprofloxacin + tizanidine	Severe hypotension, sedation	CYP1A2 inhibition	Major	Avoid; does not apply to other fluoroquinolones
Rifampin + oral contraceptives	Contraceptive failure	CYP3A4 induction	Major	Use alternative contraception (IUD, barrier)
Rifampin + opioids	Opioid withdrawal	CYP3A4 induction (reduced opioid levels)	Moderate	Increase opioid dose as needed
Macrolides (except azithromycin) + statins	Rhabdomyolysis risk	CYP3A4 inhibition	Major	Hold statin during macrolide course

CNS Drug Interactions

Drug Pair	Interaction	Mechanism	Severity	Management
MAOIs + SSRIs	Serotonin syndrome	Excessive 5-HT	Major	2-week washout (5-week for fluoxetine)
MAOIs + tyramine-rich foods	Hypertensive crisis	MAO-A inhibition (GI/liver)	Major	Dietary counseling, avoid aged cheeses, cured meats, fermented foods
MAOIs + meperidine	Serotonin syndrome, hyperpyrexia	5-HT, NE excess	Major	Avoid all serotonergic opioids
Lithium + NSAIDs	Lithium toxicity	Decreased renal Li clearance	Major	Use acetaminophen, monitor Li levels
Lithium + thiazides	Lithium toxicity	Increased Na reabsorption -> Li reabsorption	Major	Reduce Li dose 30-50%; monitor levels
Lithium + ACEi/ARB	Lithium toxicity	Decreased GFR, increased Li reabsorption	Major	Monitor Li levels closely; avoid if possible
SSRIs + NSAIDs	Increased bleeding risk	Serotonin depletion of platelet granules + COX inhibition	Moderate	Consider PPI; monitor for GI bleeding
Alcohol + benzodiazepines	Respiratory depression, sedation	Additive GABA potentiation	Major	Avoid; respiratory depression risk especially with IV benzodiazepines

Drug-Food Interactions

Food	Affected Drugs	Mechanism	Recommendation
Grapefruit juice	Statins (simvastatin, atorvastatin, lovastatin), CCBs (felodipine, nifedipine), immunosuppressants (cyclosporine), buspirone, midazolam, triazolam	Irreversible intestinal CYP3A4 inhibition	Avoid grapefruit if taking these drugs
Vitamin K-rich foods	Warfarin	Antagonizes warfarin’s vitamin K inhibition	Maintain consistent intake; INR monitoring
Tyramine-rich foods (aged cheese, cured meats, sauerkraut, soy sauce, tap beer)	MAOIs	Hypertensive crisis	Strict dietary counseling when on MAOIs
Calcium-rich foods	Tetracyclines, fluoroquinolones	Chelation, reduced absorption	Separate by 2-4 hours
High-fat meals	Griseofulvin, some HIV PIs, bexarotene	Enhanced absorption	Take with food
High-fat meals	Alendronate, ibandronate (bisphosphonates)	Reduced absorption	Take on empty stomach with water only
Caffeine	Theophylline, clozapine, olanzapine	Additive CNS stimulation; reduced clearance	Limit caffeine intake; monitor for toxicity
Licorice (glycyrrhizic acid)	Digoxin, antihypertensives	Hypokalemia, increased digoxin toxicity, reduced antihypertensive efficacy	Avoid or limit licorice intake

Risk Factors for Drug Interactions

Patient Factor	Risk	Mechanism
Older age (>65 years)	High	Polypharmacy, decreased clearance, decreased homeostatic reserve
Polypharmacy (>5 medications)	Very high	Exponential increase in potential DDI pairs
Multiple comorbidities	High	Renal/hepatic impairment, altered PK/PD
Critical illness	High	Organ dysfunction, multiple medications, rapid dose changes
Genetic polymorphisms	Variable	CYP2C19, CYP2D6, CYP2C9, HLA-B*5701, etc.
Narrow therapeutic index drugs	High	Warfarin, lithium, digoxin, theophylline
Hepatic impairment	High	Reduced metabolism, altered protein binding
Renal impairment	High	Reduced elimination of renally-cleared drugs

Prevention and Management Strategies

Strategy	Description	Example
Thorough medication reconciliation	Complete list of all medications, OTC, supplements	At every visit and transition of care
DDI screening software	Use electronic health record tools	Many EHRs flag potential DDIs
High-risk pair avoidance	Prescribe alternatives when possible	Pantoprazole instead of omeprazole with clopidogrel
Dose adjustment	Adjust dose of substrate when inhibitor/inducer is added	Reduce warfarin when starting amiodarone
Monitoring	Check levels, INR, glucose, other parameters	Monitor INR when changing interacting drugs
Temporal separation	Separate doses of interacting drugs	Tetracycline and calcium separate by 2-4 hours
Patient education	Teach patients about DDI risks	Grapefruit juice warning with statins
Therapeutic alternatives	Choose drugs with fewer DDI potential	Rosuvastatin vs. simvastatin; azithromycin vs. clarithromycin
Medication review by pharmacist	Clinical pharmacist review for high-risk patients	Polypharmacy review in elderly

Severity Classification

Severity	Description	Action
Contraindicated	Should not be combined	Avoid combination; choose alternative
Major	May cause severe toxicity or therapeutic failure	Monitor closely; adjust dose; consider alternative
Moderate	May exacerbate underlying condition or require dose adjustment	Monitor; educate patient; adjust dose if needed
Minor	Limited clinical effect	No action typically needed; monitor if patient is high-risk

Conclusion

Drug-drug interactions are a significant cause of adverse events, particularly in patients with polypharmacy. CYP450 enzyme interactions are the most common mechanism, with CYP3A4, CYP2D6, CYP2C9, and CYP2C19 responsible for the majority. Prevention requires thorough medication reconciliation, use of screening tools, knowledge of high-risk drug pairs, and proactive monitoring. P-glycoprotein and pharmacodynamic interactions add further complexity. A systematic approach to assessing and managing DDIs is essential for safe prescribing.